Effect of glucose metabolism disorders on the short-term prognosis in neonates with asphyxia: a multicenter study in Hubei Province, China / 中国当代儿科杂志

OBJECTIVES@#To study the effect of glucose metabolism disorders on the short-term prognosis in neonates with asphyxia.@*METHODS@#A retrospective analysis was performed on the medical data of the neonates with asphyxia who were admitted to 52 hospitals in Hubei Province of China from January to December, 2018 and had blood glucose data within 12 hours after birth. Their blood glucose data at 1, 2, 6, and 12 hours after birth (with an allowable time error of 0.5 hour) were recorded. According to the presence or absence of brain injury and/or death during hospitalization, the neonates were divided into a poor prognosis group with 693 neonates and a good prognosis group with 779 neonates. The two groups were compared in the incidence of glucose metabolism disorders within 12 hours after birth and short-term prognosis.@*RESULTS@#Compared with the good prognosis group, the poor prognosis group had a significantly higher proportion of neonates from secondary hospitals (48.5% vs 42.6%, @*CONCLUSIONS@#Recurrent hyperglycemia in neonates with asphyxia may suggest poor short-term prognosis, and it is necessary to strengthen the early monitoring and management of the nervous system in such neonates.

Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer

To evaluate the changes and the prognostic value of serum vascular endothelial growth factor [VEGF] in patients with differentiated thyroid cancer [DTC] . A total of 79 patients with DTC and 30 healthy individuals were divided into four groups: [1] a healthy control group [n = 30]; [2] DTC without recurrence [n = 35; 23 papillary, 12 follicular] ; [3] DTC with local recurrence [n = 24; 15 papillary, 9 follicular], and [4] DTC with lung metastasis [n = 20; 13 papillary, 7 follicular] . Serum VEGF and thyroglobulin levels were measured in all patients. Serum levels of VEGF were significantly higher in the lung metastasis group than in the other three groups [p < 0.05]. Serum thyroglobulin concentration positively correlated with VEGF expression [r = 0.8678, p < 0.001] in patients with thyroid cancer recurrence. Multivariate Cox regression analysis showed that clinical staging [OR = 1.851, 95% Cl 1.04-3.47; p = 0.038], non-compliance with postoperative thyroxin replacement therapy [OR = 1.935,95% Cl 1.03-3.65; p = 0.042] and postoperative levels of thyroglobulin [OR = 1.892, 95% Cl 1.01-3.56, p =0.032] were independent predictors for thyroid cancer recurrence. Every additional 100 ng/l of serum VEGF levels increased the risk of thyroid cancer recurrence by 20.3%; but this did not reach statistical significance [OR = 1.203, 95% Cl 0.95-1.52; p = 0.125] . Serum VEGF increased in patients with recurrent thyroid cancer following surgical therapies. The predictive value of serum VEGF requires further investigation